LaNova Medicines
China - Shanghai
BiotechnologyFocus: Cancer Targeting Antibodies
LaNova Medicines is a life sciences company focused on Cancer Targeting Antibodies.
Oncology
Funding Stage
SERIES B
Open Jobs
1
Pipeline & Clinical Trials
LM-061
Advanced TumoursClinical Trials (1)
NCT04737122Study of LM-061 in Subjects in Advanced Tumors
Phase 1Drugļ¼LM-102
Advanced Solid TumorsClinical Trials (1)
NCT04735796Study of LM-102 in Subjects in Advanced Tumors
Phase 1LM-108
Advanced Solid TumorClinical Trials (1)
NCT05199753Study of LM-108 as a Single Agent or in Combination With Anti-PD-1 Antibody in Subjects With Advanced Solid Tumours
Phase 1/2LM-2417
Advanced Solid TumorClinical Trials (1)
NCT06682780A Phase I/II Study of LM-2417 in Subjects With Advanced Solid Tumours
Phase 1/2LM-102 Injection
Advanced Solid TumorClinical Trials (1)
NCT05008445Study of LM-102 in Patients With Advance Solid Tumors
Phase 1/2LM-302
Advanced Solid TumorClinical Trials (1)
NCT05188664Study of LaNova Medicines(LM)-302 in Combination With Toripalimab in Patients With Advanced Solid Tumors
Phase 1/2LM-24C5
Advanced Solid TumorClinical Trials (1)
NCT06187402A Study of LM-24C5 For Advanced Solid Tumors
Phase 1/2LM-168
Advanced Solid TumoursClinical Trials (1)
NCT06868199A Study of LM-168 as a Single Agent or in Combination With Toripalimab in Subjects With Advanced Solid Tumours
Phase 1/2LM-061
Advanced TumoursClinical Trials (1)
NCT04882176A Clinical Study Preliminary Efficacy of LM-061 Tablet in Subjects With Advanced Tumours
Phase 1/2LM-302 Injection
Advanced Solid TumorClinical Trials (1)
NCT05161390Study of LM-302 in Patients With Advance Solid Tumors
Phase 1/2LM-108
Advanced Solid TumorClinical Trials (1)
NCT05255484Study of LM-108 as a Single Agent or in Combination With Pembrolizumab in Subjects With Advanced Solid Tumours
Phase 1/2Phase 1/2
Clinical Trials (1)
NCT05647512Study of LM-305 in Patients With Relapsed or Refractory Multiple Myeloma (RRMM) and Other Plasma Cell Diseases
Phase 1/2LM-350 for injection
Malignant TumorsClinical Trials (1)
NCT07112222A Study of LM-350 in Subjects With Advanced Solid Tumours
Phase 1/2LM101
Malignant TumorsClinical Trials (1)
NCT05615974A Phase I/II Study of LM-101 Injection in Patients With Advanced Malignant Tumors
Phase 1/2LM-108
Advanced Solid TumorClinical Trials (1)
NCT05518045A Study of LM-108 as Monotherapy or in Combination With Antitumor Therapies in Subjects With Advanced Solid Tumors
Phase 1/2LM-299
Malignant TumorsClinical Trials (1)
NCT06650566Study of LM-299 in Subjects Advanced Malignant Tumors
Phase 1/2LM-108
Advanced Solid TumorPhase 2
Clinical Trials (1)
NCT05934331A LM-302 Combination With Other Anti-Tumor Therapies Phase ll Study
Phase 2LM-24C5
Advanced Solid Tumor CancerClinical Trials (1)
NCT07387081Phase II Study of LM-24C5
Phase 2LM-108 in combination with Toripalimab
Locally Advanced or Metastatic GC and GCJ AdenocarcinomaClinical Trials (1)
NCT07362186LM-108 in Combination With Toripalimab Versus Paclitaxel Injection for the Treatment of Subjects With CCR8-Positive Gastric and Gastroesophageal Junction Adenocarcinoma
Phase 3Clinical Trials (1)
NCT06351020LM-302 for the Treatment of Subjects With Claudin18.2-Positive Gastric and Gastroesophageal Junction Adenocarcinoma.
Phase 3Open Jobs (1)
Interview Prep Quick Facts
Founded: 2019
Portfolio: 20 clinical trials
Open Roles: 1 active job